These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31608481)

  • 21. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
    Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
    Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
    J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical shock strategies to reactivate latent HIV-1: an update.
    Darcis G; Van Driessche B; Van Lint C
    Curr Opin HIV AIDS; 2016 Jul; 11(4):388-93. PubMed ID: 27259046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Current Status of Latency Reversing Agents for HIV-1 Remission.
    Rodari A; Darcis G; Van Lint CM
    Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity.
    Ishii T; Kobayakawa T; Matsuda K; Tsuji K; Ohashi N; Nakahata S; Noborio A; Yoshimura K; Mitsuya H; Maeda K; Tamamura H
    Eur J Med Chem; 2023 Aug; 256():115449. PubMed ID: 37224601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
    Bricker KM; Chahroudi A; Mavigner M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Between a shock and a hard place: challenges and developments in HIV latency reversal.
    Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
    Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV latency reversal agents: A potential path for functional cure?
    Lopes JR; Chiba DE; Dos Santos JL
    Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
    Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
    Rasmussen TA; Lewin SR
    Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.